Infliximab therapy reduces periodontoid rheumatoid pannus formation.
Robinson
A J
AJ
Taylor
D H
DH
Wright
G D
GD
D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy*; D002097:C-Reactive Protein / Q000378:metabolism; D002574:Cervical Vertebrae / Q000473:pathology; D005260:Female; D006801:Humans; D000069285:Infliximab; D008279:Magnetic Resonance Imaging; D010003:Osteoarthritis / Q000097:blood / Q000150:complications / Q000188:drug therapy / Q000473:pathology; D010510:Periodontal Diseases / Q000209:etiology / Q000517:prevention & control*
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D002097:C-Reactive Protein; D000069285:Infliximab